An Intriguing Case of Catamenial Anaphylaxis Treated with Omalizumab During Peri-Menopausal Period

In: Indian Journal of Drugs in Dermatology · 2023 · vol. 9(1) , pp. 38–39 · doi:10.4103/ijdd.ijdd_22_23 · W4386124143
article OA: diamond CC0
AI-generated summary by gemini-2.5-flash-lite, 2026-08-02

This case report describes a peri-menopausal woman experiencing catamenial anaphylaxis, a rare condition of allergic reactions linked to the menstrual cycle, which was effectively managed with omalizumab treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (5)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK